Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Zai Lab Reports Positive Topline Data From Phase 3 Bridging Trial Evaluating Karxt For The Treatment Of Schizophrenia In China

Oct 29 (Reuters) - Zai Lab Ltd  9688.HK :
    * ZAI LAB REPORTS POSITIVE TOPLINE DATA FROM PHASE 3
BRIDGING
TRIAL EVALUATING KARXT FOR THE TREATMENT OF SCHIZOPHRENIA IN
CHINA
    * ZAI LAB LTD - TRIAL MEETS ALL SECONDARY ENDPOINTS WITH
SIGNIFICANT REDUCTIONS IN SCHIZOPHRENIA SYMPTOMS
    * ZAI LAB LTD - KARXT SHOWS TOLERABLE SAFETY PROFILE WITH NO
NEW
SAFETY SIGNALS
    * ZAI LAB LTD - KARXT SHOWS 9.2-POINT REDUCTION IN PANSS
TOTAL
SCORE AT WEEK 5 VERSUS PLACEBO
    * ZAI LAB LTD - TO SUBMIT NDA FOR KARXT TO NMPA IN EARLY
2025

Source text:  ID:nBw4H2m5wa 
Further company coverage:  9688.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Zai Lab

See all news